Physician profile
Shapour Steve Mirmanesh
NPI 1669407375
$1,144.67
in general payments reported to CMS, 2019-2025
11 companies · $71.29 in 2025
The $71.29 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $273 · 2021: $157 · 2022: $241 · 2023: $45.28 · 2025: $71.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $116.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $242.25 | 2019 | |
| Esperion Therapeutics, INC. | $228.63 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $202.17 | 2019-2023 | Seglentis, Livalo |
| Antares Pharma, INC. | $146.75 | 2022 | |
| Janssen Pharmaceuticals, INC | $99.15 | 2019-2023 | Xarelto |
| Philips North America LLC | $82.89 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.29 | 2025 | |
| Pfizer INC. | $25.33 | 2021-2022 | |
| Abbvie INC. | $16.99 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $15.00 | 2020 | |
| Melinta Therapeutics, LLC | $14.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shapour Mirmanesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.